AzTrials
AzTrials

Diffuse Large B-Cell LymphomaPhase 3NCT06717347

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

A Phase 3 study testing Zilovertamab vedotin, Rituximab and Cyclophosphamide in people with Diffuse Large B-Cell Lymphoma, run by Merck Sharp & Dohme LLC at 285 sites in 35 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diffuse Large B-Cell Lymphoma
What is being tested?
Zilovertamab vedotin, Rituximab and Cyclophosphamide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,046 participants
Where
285 sitesin 35 countries
Study dates
27 Jan 2025to 29 Mar 2032
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues
  • Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
  • Has received no prior treatment for their DLBCL
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization
  • Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
  • Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Who cannot join

  • Has a history of transformation of indolent disease to DLBCL
  • Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma
  • Has Ann Arbor Stage I DLBCL
  • Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
  • Has clinically significant pericardial or pleural effusion
  • Has ongoing Grade >1 peripheral neuropathy
Show all 16Show fewer
  • Has a demyelinating form of Charcot-Marie-Tooth disease
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has ongoing corticosteroid therapy
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Known active central nervous system (CNS) lymphoma
  • Has active autoimmune disease that has required systemic treatment in the past 2 years
  • Has active infection requiring systemic therapy
  • Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection
  • Has history of allogeneic tissue/solid organ transplant

Trial locations and contacts

285 sites in 35 countries. Contact the study team or a site near you to ask about taking part.

Toll Free Number contact

1-888-577-8839

Trialsites@msd.com

285 sites in 35 countries

United States61 sites, 59 recruiting

  • New York Oncology Hematology, P.C. ( Site 0129)

    Albany, New York, 12206

    Study Coordinator, 518-262-6696

    Recruiting

  • CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184)

    Alexandria, Louisiana, 71301

    Study Coordinator, 318-448-6917

    Recruiting

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545)

    Ann Arbor, Michigan, 48106

    Study Coordinator, 734-712-1000

    Recruiting

  • University Cancer & Blood Center, LLC ( Site 0141)

    Athens, Georgia, 30607

    Study Coordinator, 706-353-2990

    Recruiting

  • New Jersey Cancer Care ( Site 7002)

    Belleville, New Jersey, 07109

    Study Coordinator, 973-751-8880

    Recruiting

  • American Oncology Partners, P.A. ( Site 0185)

    Bethesda, Maryland, 20817

    Study Coordinator, 301-571-2016

    Recruiting

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178)

    Billings, Montana, 59102

    Study Coordinator, 406-238-6685

    Recruiting

  • Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166)

    Bridgeton, Missouri, 63044

    Study Coordinator, 636-673-3083

    Recruiting

  • University of Virginia Cancer Center ( Site 0138)

    Charlottesville, Virginia, 22903

    Study Coordinator, 434-243-7773

    Recruiting

  • Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002)

    Cincinnati, Ohio, 45242

    Study Coordinator, 513-751-2273

    Recruiting

  • Clermont Oncology Center ( Site 0182)

    Clermont, Florida, 34711

    Study Coordinator, 352-242-1366

    Recruiting

  • Maryland Oncology Hematology (MOH) ( Site 8004)

    Columbia, Maryland, 21044

    Study Coordinator, 00000000

    Recruiting

  • Texas Oncology - DFW ( Site 8000)

    Dallas, Texas, 75246

    Study Coordinator, 214-370-1000

    Recruiting

  • Karmanos Cancer Institute ( Site 0174)

    Detroit, Michigan, 48201

    Study Coordinator, 800-527-6266

    Recruiting

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001)

    Eugene, Oregon, 97401

    Study Coordinator, 541-683-5001

    Recruiting

  • Sanford Health Roger Maris Cancer Center ( Site 0189)

    Fargo, North Dakota, 58102

    Study Coordinator, 701-234-6161

    Recruiting

  • Fort Wayne Medical Oncology and Hematology ( Site 0149)

    Fort Wayne, Indiana, 46804

    Study Coordinator, 260-436-0800

    Recruiting

  • Providence Medical Foundation-Oncology ( Site 0168)

    Fullerton, California, 92835

    Study Coordinator, 714-446-5900

    Recruiting

  • Banner MD Anderson Cancer Center ( Site 0165)

    Gilbert, Arizona, 85234

    Study Coordinator, 480-256-6444

    Recruiting

  • Lutheran Hospital - Cancer Centers of Colorado ( Site 0180)

    Golden, Colorado, 80401

    Study Coordinator, 303-403-6381

    Recruiting

  • Corewell Health ( Site 0130)

    Grand Rapids, Michigan, 49503

    Study Coordinator, 616-486-6180

    Recruiting

  • East Carolina University ( Site 0159)

    Greenville, North Carolina, 27834

    Study Coordinator, 252-816-2273

    Recruiting

  • Prisma Health - Upstate ( Site 0158)

    Greenville, South Carolina, 29605

    Study Coordinator, 864-679-3900

    Recruiting

  • Virginia Oncology Associates (VOA) ( Site 8005)

    Hampton, Virginia, 23666

    Study Coordinator, 757-827-9400

    Recruiting

  • Bioresearch Partner ( Site 0157)

    Hialeah, Florida, 33013

    Study Coordinator, 833-489-4968

    Recruiting

  • Center for Oncology and Blood Disorders ( Site 0153)

    Houston, Texas, 77030

    Completed

  • Houston Methodist Cancer Center ( Site 0154)

    Houston, Texas, 77030

    Study Coordinator, 713-363-8009

    Recruiting

  • The University of Mississippi Medical Center ( Site 0161)

    Jackson, Mississippi, 39216

    Study Coordinator, 601-984-5601

    Recruiting

  • Truman Medical Center ( Site 0122)

    Kansas City, Missouri, 64108

    Study Coordinator, 816-404-4418

    Recruiting

  • The University of Tennessee Medical Center ( Site 0142)

    Knoxville, Tennessee, 37920

    Study Coordinator, 865-305-9000

    Recruiting

  • OptumCare Cancer Care ( Site 0121)

    Las Vegas, Nevada, 89102

    Study Coordinator, 702-724-8787

    Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 0113)

    Las Vegas, Nevada, 89169

    Study Coordinator, 702-622-9699

    Recruiting

  • University of Kentucky ( Site 0106)

    Lexington, Kentucky, 40536

    Study Coordinator, 859-257-6006

    Recruiting

  • MemorialCare Health System - Long Beach Medical Center ( Site 9559)

    Long Beach, California, 90806

    Study Coordinator, 652-241-9755

    Recruiting

  • Cancer Blood and Specialty Clinic ( Site 0109)

    Los Alamitos, California, 90720

    Study Coordinator, 562-200-0203

    Recruiting

  • Cedars-Sinai Medical Center ( Site 0115)

    Los Angeles, California, 90048

    Study Coordinator, 310-423-3277

    Recruiting

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163)

    Louisville, Kentucky, 40207

    Study Coordinator, 502-899-3366

    Recruiting

  • Joe Arrington Cancer Research and Treatment Center ( Site 0183)

    Lubbock, Texas, 79410

    Study Coordinator, 806-725-8000

    Recruiting

  • SSM Health Dean Medical Group ( Site 0140)

    Madison, Wisconsin, 53715

    Study Coordinator, 608-410-2700

    Recruiting

  • USA Mitchell Cancer Institute ( Site 0173)

    Mobile, Alabama, 36604

    Study Coordinator, 251-445-9875

    Recruiting

  • Edward Cancer Center ( Site 0197)

    Naperville, Illinois, 60540

    Study Coordinator, 630-527-3788

    Recruiting

  • SCRI Oncology Partners ( Site 7000)

    Nashville, Tennessee, 37203

    Study Coordinator, 629-309-0339

    Recruiting

  • Icahn School of Medicine at Mount Sinai ( Site 0164)

    New York, New York, 10029

    Study Coordinator, 212-241-6500

    Recruiting

  • Cancer Care Specialists of Illinois ( Site 0152)

    O'Fallon, Illinois, 62269

    Study Coordinator, 618-416-7970

    Recruiting

  • Orlando Health Cancer Institute ( Site 0169)

    Ocoee, Florida, 34761

    Study Coordinator, 321-843-7497

    Recruiting

  • Vista Oncology ( Site 4201)

    Olympia, Washington, 98506

    Study Coordinator, 360-413-8880

    Recruiting

  • Mid Florida Hematology and Oncology Center ( Site 0172)

    Orange City, Florida, 32763

    Study Coordinator, 386-774-1223

    Recruiting

  • Owensboro Medical Health System ( Site 0195)

    Owensboro, Kentucky, 42303

    Study Coordinator, 270-688-1938

    Recruiting

  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)

    Phoenix, Arizona, 85006

    Study Coordinator, 480-256-6444

    Recruiting

  • Kaiser Permanente Interstate Medical Office - Central ( Site 0181)

    Portland, Oregon, 97227

    Study Coordinator, 503-331-5600

    Recruiting

  • Cancer Care Specialists ( Site 9582)

    Reno, Nevada, 89511

    Study Coordinator, 7753290222x230

    Recruiting

  • Virginia Cancer Institute ( Site 0148)

    Richmond, Virginia, 23229

    Study Coordinator, 804-287-3000

    Recruiting

  • Blue Ridge Cancer Care ( Site 0132)

    Roanoke, Virginia, 24014

    Study Coordinator, 540-982-0237

    Recruiting

  • Pacific Hematology Oncology Associates ( Site 0131)

    San Francisco, California, 94115

    Study Coordinator, 415-923-3012

    Recruiting

  • New York Cancer and Blood Specialists ( Site 9000)

    Shirley, New York, 11967

    Study Coordinator, 631-675-5075

    Recruiting

  • Sanford Cancer Center ( Site 0143)

    Sioux Falls, South Dakota, 57104

    Study Coordinator, 605-328-8000

    Recruiting

  • Oncology and Hematology Associates ( Site 9546)

    Springfield, Missouri, 65807

    Study Coordinator, 417-882-4880

    Recruiting

  • Tampa General Hospital ( Site 0134)

    Tampa, Florida, 33606

    Study Coordinator, 813-844-7585

    Recruiting

  • Texas Oncology - Gulf Coast ( Site 8003)

    The Woodlands, Texas, 77380

    Study Coordinator, 281-296-0365

    Recruiting

  • Cotton O'Neil Cancer Center ( Site 0108)

    Topeka, Kansas, 66606

    Completed

  • The University of Arizona Cancer Center - North Campus ( Site 0124)

    Tucson, Arizona, 85719

    Study Coordinator, 520-621-5497

    Recruiting

Other trials in United States

China24 sites, 23 recruiting

  • Peking University Third Hospital ( Site 3102)

    Beijing, Beijing Municipality, 100096

    Study Coordinator, 010-82266699

    Recruiting

  • Beijing Cancer Hospital ( Site 3101)

    Beijing, Beijing Municipality, 100142

    Study Coordinator, 010-88121122

    Recruiting

  • The First Hospital Of Jilin University ( Site 3103)

    Changchun, Jilin, 130021

    Study Coordinator, 0431-88782222

    Recruiting

  • Sichuan Cancer Hospital. ( Site 3111)

    Chengdu, Sichuan, 610041

    Study Coordinator, 02885420243

    Recruiting

  • West China Hospital, Sichuan University ( Site 3110)

    Chengdu, Sichuan, 610041

    Study Coordinator, 028-85422114

    Recruiting

  • Chongqing Cancer Hospital ( Site 3113)

    Chongqing, Chongqing Municipality, 400030

    Study Coordinator, 023-65301682

    Recruiting

  • Fujian Provincial Cancer Hospital. ( Site 3119)

    Fuzhou, Fujian, 350014

    Study Coordinator, 059162752082

    Recruiting

  • Sun Yat-sen University Cancer Center ( Site 3121)

    Guangzhou, Guangdong, 510060

    Study Coordinator, 020-87343765

    Recruiting

  • Zhujiang Hospital of Southern Medical University ( Site 3122)

    Guangzhou, Guangdong, 510280

    Study Coordinator, 020-62782020

    Recruiting

  • The Affiliated Hospital of Guizhou Medical University ( Site 3112)

    Guiyang, Guizhou, 550004

    Study Coordinator, 0851-86740793

    Recruiting

  • The First Affiliated Hospital, Zhejiang Medical University ( Site 3116)

    Hangzhou, Zhejiang, 310009

    Study Coordinator, 0571-87236668

    Recruiting

  • Anhui Provincial Cancer Hospital ( Site 3124)

    Hefei, Anhui, 230031

    Study Coordinator, +8655165327666

    Recruiting

  • Shandong Cancer Hospital ( Site 3108)

    Jinan, Shandong, 250117

    Study Coordinator, +8613642138692

    Recruiting

  • Yunnan Province Cancer Hospital ( Site 3109)

    Kunming, Yunnan, 650118

    Study Coordinator, 0871-68185656

    Recruiting

  • LinYi Cancer Hospital ( Site 3104)

    Linyi, Shandong, 276001

    Study Coordinator, +865398127192

    Recruiting

  • Jiangxi Cancer Hospital ( Site 3118)

    Nanchang, Jiangxi, 330029

    Study Coordinator, 0791-88317256

    Recruiting

  • Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123)

    Nanning, Guangxi, 530021

    Study Coordinator, 0771-5323002

    Recruiting

  • Affiliated Hospital of Nantong University ( Site 3117)

    Nantong, Jiangsu, 226001

    Study Coordinator, +8618252100915

    Recruiting

  • Fudan University Shanghai Cancer Center ( Site 3115)

    Shanghai, Shanghai Municipality, 200032

    Study Coordinator, +862164175590

    Recruiting

  • Shanxi Cancer Hospital ( Site 3106)

    Taiyuan, Shanxi, 030013

    Completed

  • Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105)

    Tianjin, Tianjin Municipality, 301617

    Study Coordinator, 022 23608030

    Recruiting

  • Hubei Cancer Hospital ( Site 3125)

    Wuhan, Hubei, 430079

    Study Coordinator, 027-87670003

    Recruiting

  • 1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 3107)

    Xi’an, Shanxi, 710061

    Study Coordinator, 029-85324094

    Recruiting

  • The First Affiliated Hospital of Xiamen University ( Site 3120)

    Xiamen, Fujian, 361003

    Study Coordinator, +8605922137255

    Recruiting

Other trials in China

Japan20 sites, 20 recruiting

  • Juntendo University Hospital ( Site 3307)

    Bunkyo, Tokyo, 113-8431

    Study Coordinator, +81-3-3813-3111

    Recruiting

  • Tokyo Metropolitan Komagome Hospital ( Site 3323)

    Bunkyo, Tokyo, 113-8677

    Study Coordinator, +81-3-3823-2101

    Recruiting

  • Chiba Cancer Center ( Site 3314)

    Chiba, 260-8717

    Study Coordinator, +81-43-264-5431

    Recruiting

  • University of Yamanashi Hospital ( Site 3320)

    Chūō, Yamanashi, 409-3898

    Study Coordinator, +81-55-273-1111

    Recruiting

  • Kyushu University Hospital ( Site 3313)

    Fukuoka, 812-8582

    Study Coordinator, +8192-641-1151

    Recruiting

  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 3322)

    Hiroshima, 730-8619

    Study Coordinator, +81-82-241-3111

    Recruiting

  • Saitama Medical University Hospital ( Site 3305)

    Iruma-gun, Saitama, 350-0495

    Study Coordinator, +81-49-276-1111

    Recruiting

  • Tokai University Hospital ( Site 3302)

    Isehara, Kanagawa, 259-1193

    Study Coordinator, +81-463-93-1121

    Recruiting

  • Kanazawa University Hospital ( Site 3308)

    Kanazawa, Ishikawa-ken, 920-8641

    Study Coordinator, +81-76-265-2000

    Recruiting

  • National Cancer Center Hospital East ( Site 3303)

    Kashiwa, Chiba, 277-8577

    Study Coordinator, +81-4-7133-1111

    Recruiting

  • Kobe City Medical Center General Hospital ( Site 3318)

    Kobe, Hyōgo, 650-0047

    Study Coordinator, +81-78-302-4321

    Recruiting

  • University Hospital,Kyoto Prefectural University of Medicine ( Site 3315)

    Kyoto, 602-8566

    Study Coordinator, +81-75-251-5111

    Recruiting

  • National Hospital Organization Shikoku Cancer Center ( Site 3321)

    Matsuyama, Ehime, 791-0280

    Study Coordinator, +81-89-999-1111

    Recruiting

  • University of Miyazaki Hospital ( Site 3319)

    Miyazaki, 889-1692

    Study Coordinator, +81-985-85-1510

    Recruiting

  • Nagoya University Hospital ( Site 3309)

    Nagoya, Aichi-ken, 466-8560

    Study Coordinator, +81-52-741-2111

    Recruiting

  • Okayama University Hospital ( Site 3311)

    Okayama, 700-8558

    Study Coordinator, +81-86-223-7151

    Recruiting

  • Osaka Metropolitan University Hospital ( Site 3317)

    Osaka, 545-8586

    Study Coordinator, +81-6-6645-2121

    Recruiting

  • Kindai University Hospital ( Site 3310)

    Sakai, Osaka, 590-0197

    Study Coordinator, +81-72-288-7222

    Recruiting

  • Tohoku University Hospital ( Site 3301)

    Sendai, Miyagi, 980-8574

    Study Coordinator, +81-22-717-7000

    Recruiting

  • Yamagata University Hospital ( Site 3312)

    Yamagata, 990-9585

    Study Coordinator, +81-23-633-1122

    Recruiting

Other trials in Japan

France14 sites, 14 recruiting

  • Centre Hospitalier d'Avignon ( Site 1505)

    Avignon, Vaucluse, 84000

    Study Coordinator, 33432759330

    Recruiting

  • Centre Hospitalier de la Cote Basque ( Site 1509)

    Bayonne, Pyrenees-Atlantiques, 64100

    Study Coordinator, +33533788254

    Recruiting

  • Centre Hospitalier Universitaire Estaing ( Site 1508)

    Clermont-Ferrand, Puy-de-Dome, 63100

    Study Coordinator, 33473752291

    Recruiting

  • CHU Dijon Bourgogne ( Site 1516)

    Dijon, Cote-d Or, 21000

    Study Coordinator, +33380669237

    Recruiting

  • Centre Hospitalier de Dunkerque ( Site 1513)

    Dunkirk, Nord, 59385

    Study Coordinator, +330328285633

    Recruiting

  • CHD Vendee ( Site 1502)

    La Roche-sur-Yon, Vendee, 85000

    Study Coordinator, +33251446173

    Recruiting

  • Hopital Saint Louis, Centre Hospitalier de La Rochelle ( Site 1511)

    La Rochelle, Charente-Maritime, 17000

    Study Coordinator, +33546458867.

    Recruiting

  • CHU GRENOBLE ALPES ( Site 1518)

    La Tronche, Isere, 38700

    Study Coordinator, +33476765755

    Recruiting

  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1512)

    Limoges, Limousin, 87042

    Study Coordinator, +33555056651

    Recruiting

  • Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy ( Site 1515)

    Metz, Moselle, 57085

    Study Coordinator, +33387553363

    Recruiting

  • Centre Antoine-Lacassagne ( Site 1514)

    Nice, Alpes-Maritimes, 06189

    Study Coordinator, +33492031000

    Recruiting

  • Centre Henri Becquerel ( Site 1517)

    Rouen, Seine-Maritime, 76038

    Study Coordinator, 02.76.67.30.45

    Recruiting

  • Institut Curie - site Saint-Cloud ( Site 1501)

    Saint-Cloud, Île-de-France Region, 92210

    Study Coordinator, 01 47 11 17 92

    Recruiting

  • HIA Sainte Anne ( Site 1506)

    Toulon, Var, 83800

    Study Coordinator, +33483162506

    Recruiting

Other trials in France

Spain13 sites, 12 recruiting

  • Hospital General Universitario Dr. Balmis ( Site 2604)

    Alicante, Valenciana, Comunitat, 03010

    Study Coordinator, 34965913727

    Recruiting

  • Hospital de Cruces ( Site 2612)

    Barakaldo, Bizkaia, 48903

    Study Coordinator, +34946006000

    Recruiting

  • Hospital del Mar ( Site 2610)

    Barcelona, 08003

    Study Coordinator, 34932483343

    Recruiting

  • Hospital de Cabuenes ( Site 2613)

    Gijón, Principality of Asturias, 33394

    Study Coordinator, +34985185000

    Recruiting

  • ICO L Hospitalet ( Site 2601)

    L'Hospitalet de Llobregat, Barcelona, 08908

    Study Coordinator, 932607750

    Recruiting

  • H. Insular de Gran Canaria ( Site 2606)

    Las Palmas de Gran Canaria, Las Palmas, 35016

    Study Coordinator, 0034928441738

    Recruiting

  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2614)

    Madrid, 28007

    Study Coordinator, +34915868000

    Recruiting

  • Hospital General Universitario 12 de Octubre ( Site 2605)

    Madrid, 28041

    Study Coordinator, +34605532453

    Recruiting

  • Hospital Universitario La Paz ( Site 2611)

    Madrid, 28046

    Study Coordinator, 34912071518

    Recruiting

  • Hospital Universitario Puerta de Hierro ( Site 2615)

    Majadahonda, Madrid, 28222

    Study Coordinator, 34911916000

    Recruiting

  • Hospital Virgen de la Victoria ( Site 2609)

    Málaga, 29010

    Study Coordinator, 0034951032508

    Recruiting

  • Hospital Universitario Virgen Macarena ( Site 2608)

    Seville, Andalusia, 41009

    Study Coordinator, 34955054993

    Recruiting

  • Hospital Universitario Miguel Servet ( Site 2607)

    Zaragoza, 50009

    Completed

Other trials in Spain

Italy11 sites, 10 recruiting

  • AOU delle Marche Ospedali Riuniti di Ancona ( Site 2011)

    Ancona, 60126

    Completed

  • Azienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 2001)

    Brescia, 25123

    Study Coordinator, +390303995438

    Recruiting

  • INOC - Istituto Nazionale Oncologico Candiolo ( Site 2010)

    Candiolo, Torino, 10060

    Study Coordinator, +390119933250

    Recruiting

  • IRCCS Ospedale San Raffaele ( Site 2012)

    Milan, 20132

    Study Coordinator, +39 02 2643 7649

    Recruiting

  • IEO Istituto Europeo di Oncologia ( Site 2009)

    Milan, 20141

    Study Coordinator, +39 02 94371079

    Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori ( Site 2008)

    Monza, Lombardy, 20900

    Study Coordinator, +390392333539

    Recruiting

  • Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 2004)

    Novara, 28100

    Study Coordinator, +3903213733127

    Recruiting

  • Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO ( Site 2005)

    Palermo, Sicily, 90146

    Study Coordinator, +390916802773

    Recruiting

  • Ospedale Santa Maria delle Croci ( Site 2006)

    Ravenna, 48121

    Study Coordinator, +390544285722

    Recruiting

  • IRCCS Crob ( Site 2002)

    Rionero in Vulture, Potenza, 85028

    Study Coordinator, +390972726685

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 2003)

    Roma, 00168

    Study Coordinator, 00390630154180

    Recruiting

Other trials in Italy

Brazil9 sites, 9 recruiting

  • CEONC ( Site 0412)

    Cascavel, Paraná, 85803-760

    Study Coordinator, 049988422678

    Recruiting

  • Hospital Erasto Gaertner ( Site 0401)

    Curitiba, Paraná, 82520-060

    Study Coordinator, +5541999846033

    Recruiting

  • CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0403)

    Florianópolis, Santa Catarina, 88020-210

    Study Coordinator, +554833804828

    Recruiting

  • Liga Norte Riograndense Contra o Cancer ( Site 0407)

    Natal, Rio Grande do Norte, 59062-000

    Study Coordinator, +5584999278442

    Recruiting

  • Hope ( Site 0413)

    Ribeirão Preto, São Paulo, 14026-610

    Study Coordinator, +55 16 98813-0059

    Recruiting

  • Clinica Advanze ( Site 0411)

    São Carlos, São Paulo, 13561-130

    Study Coordinator, 55163371-1320

    Recruiting

  • Hospital Paulistano ( Site 0406)

    São Paulo, 01321-001

    Study Coordinator, +551131411083

    Recruiting

  • Hospital das Clinicas FMUSP ( Site 0402)

    São Paulo, 05403-010

    Study Coordinator, +5511975458304

    Recruiting

  • F. F. R. M. São Jose do Rio Preto ( Site 0404)

    SJRP, São Paulo, 15090-000

    Study Coordinator, +55 17 99788 6883

    Recruiting

Other trials in Brazil

Chile9 sites, 8 recruiting

  • Biocenter ( Site 0510)

    Concepción, Biobio, 4070196

    Study Coordinator, +56412858421

    Recruiting

  • IC La Serena Research ( Site 0504)

    La Serena, Coquimbo Region, 1720430

    Study Coordinator, +56958646664

    Recruiting

  • Centro de Estudios Clínicos SAGA ( Site 0508)

    Santiago, Region M. de Santiago, 7500653

    Study Coordinator, +56991612199

    Recruiting

  • Fundación Arturo López Pérez ( Site 0501)

    Santiago, Region M. de Santiago, 7500921

    Study Coordinator, +5622712 8000

    Recruiting

  • Clinica Inmunocel ( Site 0503)

    Santiago, Region M. de Santiago, 7580206

    Study Coordinator, +56224376600

    Recruiting

  • Clínica RedSalud Vitacura ( Site 0512)

    Santiago, Region M. de Santiago, 7650018

    Completed

  • Bradfordhill ( Site 0502)

    Santiago, Region M. de Santiago, 8420383

    Study Coordinator, +56229490970

    Recruiting

  • Oncocentro Valdivia ( Site 0506)

    Valdivia, Los Ríos Region, 5112129

    Study Coordinator, +56632632200

    Recruiting

  • Centro de Investigaciones ( Site 0511)

    Viña del Mar, Valparaiso, 2540488

    Study Coordinator, +56323245375

    Recruiting

Other trials in Chile

Argentina8 sites, 6 recruiting

  • Hospital Aleman ( Site 0301)

    Buenos Aires, Buenos Aires F.D., C1118AAT

    Study Coordinator, +541148232574

    Recruiting

  • Hospital Italiano de Buenos Aires ( Site 0304)

    CABA, C1199ABB

    Study Coordinator, (011) 4959-0550

    Recruiting

  • Clinica Adventista Belgrano ( Site 0309)

    Caba., Buenos Aires, C1430EGF

    Study Coordinator, +5491140141500

    Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0306)

    Mar del Plata, Buenos Aires, B7600FZO

    Study Coordinator, +542234963224

    Recruiting

  • Hospital Universitario Austral ( Site 0307)

    Pilar, Buenos Aires, B1629AHJ

    Study Coordinator, +541158239252

    Recruiting

  • Fundacion Estudios Clinicos ( Site 0311)

    Rosario, Santa Fe Province, S2000CEJ

    Study Coordinator, +54 (0341) 2221472

    Recruiting

  • Clinica EL Castaño ( Site 0312)

    San Juan, J5400ARW

    Completed

  • C.I.C.E. 9 de Julio ( Site 0305)

    San Miguel de Tucumán, Tucumán Province, T4000IKO

    Completed

Other trials in Argentina

Turkey (Türkiye)8 sites, 5 recruiting

  • Baskent Universitesi Adana Dr. Turgut Noyan UAM ( Site 2809)

    Adana, 01120

    Completed

  • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 2803)

    Ankara, 06200

    Study Coordinator, +90 (0312) 336 09 09

    Recruiting

  • Hacettepe Universite Hastaneleri ( Site 2810)

    Ankara, 06230

    Study Coordinator, 05322276104

    Recruiting

  • Ankara University Faculty of Medicine ( Site 2801)

    Ankara, 06620

    Study Coordinator, +903125956593

    Recruiting

  • Antalya Egitim ve Arastirma Hastanesi ( Site 2805)

    Antalya, 7100

    Completed

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi ( Site 2804)

    Istanbul, 34722

    Study Coordinator, 0090 532 408 9525

    Recruiting

  • Ondokuz Mayıs Universitesi ( Site 2806)

    Korfez Mahallesi, Samsun, 55270

    Study Coordinator, +905052722289

    Recruiting

  • Namık Kemal University Medical Faculty ( Site 2807)

    Suleymanpasa, Tekirdas, 59030

    Completed

Other trials in Turkey (Türkiye)

Mexico7 sites, 5 recruiting

  • Health Pharma Professional Research S.A. de C.V. ( Site 0801)

    Mexico City, Mexico City, 03100

    Study Coordinator, +52 5575864856

    Recruiting

  • Centro de Infusion Superare ( Site 0804)

    Mexico City, Mexico City, 03104

    Study Coordinator, 52 5552646440

    Recruiting

  • Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"" ( Site 0802)

    Monterrey, Nuevo León, 64460

    Study Coordinator, 52 8183486136

    Recruiting

  • Centro de Investigacion Clinica Chapultepec ( Site 0803)

    Morelia, Michoacán, 58260

    Study Coordinator, 52 4431478545

    Recruiting

  • Centro de Investigacion Clinica de Oaxaca ( Site 0805)

    Oaxaca City, 68020

    Study Coordinator, 52 9515473137

    Recruiting

  • Grupo Ollin Care ( Site 0806)

    Pachuca, Hidalgo, 42000

    Completed

  • CIMAB SA de CV ( Site 0807)

    Torreón, Coahuila, 27000

    Completed

Other trials in Mexico

Poland7 sites, 6 recruiting

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2208)

    Gliwice, Silesian Voivodeship, 44-102

    Study Coordinator, +48322789794

    Recruiting

  • Pratia Onkologia Katowice ( Site 2204)

    Katowice, Silesian Voivodeship, 40-519

    Study Coordinator, +48327462500

    Recruiting

  • Uniwersytecki Szpital Kliniczny nr 1 w Lublinie ( Site 2202)

    Lublin, Lublin Voivodeship, 20- 081

    Study Coordinator, 00815345468

    Recruiting

  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2205)

    Olsztyn, Warmian-Masurian Voivodeship, 10-228

    Study Coordinator, +48895398428

    Recruiting

  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 2210)

    Słupsk, Pomeranian Voivodeship, 76-200

    Study Coordinator, 59 84 60 390

    Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2201)

    Warsaw, Masovian Voivodeship, 02-781

    Completed

  • Pratia Spolka Akcyjna, Pratia Onkologia Wroclaw ( Site 2211)

    Wroclaw, Lower Silesian Voivodeship, 50-019

    Study Coordinator, 502 278 782

    Recruiting

Other trials in Poland

South Korea7 sites, 5 recruiting

  • Pusan National University Hospital ( Site 3804)

    Busan, Pusan-Kwangyokshi, 49241

    Study Coordinator, +8251-240-7839

    Recruiting

  • Chungnam National University Hospital ( Site 3801)

    Daejeon, Taejon-Kwangyokshi, 35015

    Study Coordinator, 82422806922

    Recruiting

  • National Cancer Center- Center for Hemotologic malignancy ( Site 3806)

    Goyang-si, Kyonggi-do, 10408

    Study Coordinator, 8231-920-1505

    Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 3802)

    Seoul, 03722

    Completed

  • Asan Medical Center ( Site 3803)

    Seoul, 05505

    Study Coordinator, +82230105940

    Recruiting

  • Samsung Medical Center ( Site 3807)

    Seoul, 06351

    Completed

  • St.Mary's H., Youido ( Site 3805)

    Seoul, 07345

    Study Coordinator, +82237791049

    Recruiting

Other trials in South Korea

Ukraine7 sites, 5 recruiting

  • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2904)

    Cherkasy, Cherkasy Oblast, 18009

    Study Coordinator, +38 047 2370025

    Recruiting

  • Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2906)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76008

    Study Coordinator, +380342 528029

    Recruiting

  • Khmelnytskyi Regional Hospital ( Site 2907)

    Khmelnytskiy, Khmelnytskyi Oblast, 29000

    Study Coordinator, +380382649001

    Recruiting

  • SNPE National Cancer Institute ( Site 2902)

    Kyiv, 03022

    Study Coordinator, 380443346418

    Recruiting

  • Universal Clinic Oberig ( Site 2908)

    Kyiv, 03057

    Completed

  • SI National Research Center of Radiation Medicine, Hematology, Oncology ( Site 2901)

    Kyiv, 03115

    Completed

  • Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903)

    Lviv, Lviv Oblast, 79057

    Study Coordinator, +380322373917

    Recruiting

Other trials in Ukraine

Taiwan6 sites, 5 recruiting

  • Chang Gung Memorial Hospital at Kaohsiung ( Site 3905)

    Kaohsiung City, 83301

    Study Coordinator, 886-7-7317123

    Recruiting

  • National Cheng Kung University Hospital ( Site 3902)

    Tainan, 704

    Study Coordinator, +88662353535x4620

    Recruiting

  • National Taiwan University Hospital ( Site 3901)

    Taipei, 10002

    Study Coordinator, +88623123456

    Recruiting

  • Mackay Memorial Hospital ( Site 3908)

    Taipei, 10449

    Completed

  • Tri-Service General Hospital ( Site 3906)

    Taipei, 114

    Study Coordinator, +886287927208x12903

    Recruiting

  • Chang Gung Memorial Hospital - Linkou Branch ( Site 3903)

    Taoyuan City, Taoyuan, 333

    Study Coordinator, +88633281200x2555

    Recruiting

Other trials in Taiwan

Australia5 sites, 5 recruiting

  • Royal Adelaide Hospital ( Site 3001)

    Adelaide, South Australia, 5000

    Study Coordinator, 0870745898

    Recruiting

  • Grampians Health ( Site 3003)

    Ballarat, Victoria, 3350

    Study Coordinator, +61353204000

    Recruiting

  • Northern Hospital ( Site 3002)

    Melbourne, Victoria, 3076

    Study Coordinator, +61384058000

    Recruiting

  • Royal Perth Hospital-Haematology ( Site 3004)

    Perth, Western Australia, 6000

    Study Coordinator, +61864775013

    Recruiting

  • Townsville University Hospital ( Site 3006)

    Townsville, Queensland, 4814

    Study Coordinator, +61744333549

    Recruiting

Other trials in Australia

Canada5 sites, 5 recruiting

  • Cross Cancer Institute ( Site 0205)

    Edmonton, Alberta, T6G 1Z2

    Study Coordinator, 780-432-8771

    Recruiting

  • Queen Elizabeth II Health Sciences Centre ( Site 0207)

    Halifax, Nova Scotia, B3H 2Y9

    Study Coordinator, 902-473-4642

    Recruiting

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0208)

    Hamilton, Ontario, L8V 5C2

    Study Coordinator, 9053879495

    Recruiting

  • Lakeridge Health - The R.S. McLaughlin Durham Regional Cancer Centre (MDRCC) ( Site 0206)

    Oshawa, Ontario, L1G 2B9

    Study Coordinator, 9055768711

    Recruiting

  • Sunnybrook Research Institute ( Site 0204)

    Toronto, Ontario, M4N 3M5

    Study Coordinator, 4164804662

    Recruiting

Other trials in Canada

Colombia5 sites, 4 recruiting

  • Hospital Universitario San Ignacio ( Site 0607)

    Bogotá, Bogota D.C., 110231

    Active, not recruiting

  • Fundación Valle del Lili ( Site 0602)

    Cali, Valle del Cauca Department, 760032

    Study Coordinator, 3158971414

    Recruiting

  • Hospital Pablo Tobon Uribe ( Site 0604)

    Medellín, Antioquia, 050034

    Study Coordinator, +57 604 4459753

    Recruiting

  • IMAT S.A.S ( Site 0603)

    Montería, Departamento de Córdoba, 230002

    Study Coordinator, +57 604 7832333

    Recruiting

  • Oncologos del Occidente ( Site 0601)

    Pereira, Risaralda Department, 660001

    Study Coordinator, 573002558656

    Recruiting

Other trials in Colombia

Hungary5 sites, 5 recruiting

  • Semmelweis University-Belgyógyászati és Hematológiai Klinika ( Site 1703)

    Budapest, Hajdú-Bihar, 1088

    Study Coordinator, +3614591500

    Recruiting

  • Orszagos Onkologiai Intezet ( Site 1705)

    Budapest, 1122

    Study Coordinator, +36 1 224 8600 #3775

    Recruiting

  • Debreceni Egyetem Klinikai Kozpont ( Site 1702)

    Debrecen, Hajdú-Bihar, 4032

    Study Coordinator, +3652255601

    Recruiting

  • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1704)

    Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400

    Study Coordinator, +3642599700/1060

    Recruiting

  • Tolna Vármegyei Balassa János Kórház ( Site 1710)

    Szekszárd, Tolna County, 7100

    Study Coordinator, +36 74 501 603

    Recruiting

Other trials in Hungary

Malaysia5 sites, 5 recruiting

  • Queen Elizabeth Hospital ( Site 3405)

    Kota Kinabalu, Sabah, 88586

    Study Coordinator, +6088517555

    Recruiting

  • Sarawak General Hospital ( Site 3402)

    Kuching, Sarawak, 93586

    Study Coordinator, +6082276666

    Recruiting

  • Hospital Miri ( Site 3403)

    Miri, Sarawak, 98000

    Study Coordinator, +6085460600

    Recruiting

  • Sunway Medical Centre ( Site 3406)

    Petaling Jaya, Selangor, 47500

    Study Coordinator, +60386011080

    Recruiting

  • Hospital Ampang ( Site 3404)

    Selangor Darul Ehsan, Selangor, 68000

    Study Coordinator, +60342896559

    Recruiting

Other trials in Malaysia

Peru5 sites, 3 recruiting

  • Clínicas AUNA Sede Chiclayo ( Site 0904)

    Chiclayo, Lambayeque, 14001

    Study Coordinator, 51 74748333 Ext 7832

    Recruiting

  • Clínica San Felipe ( Site 0906)

    Lima, 15072

    Study Coordinator, 511 2039900 Ext 131

    Recruiting

  • Hospital Nacional Edgardo Rebagliati Martins ( Site 0903)

    Lima, 15072

    Study Coordinator, +51991895682

    Recruiting

  • Hospital Nacional Dos De Mayo ( Site 0905)

    Lima, 15087

    Completed

  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0901)

    Surquillo, Muni Metro de Lima, 15038

    Active, not recruiting

Other trials in Peru

Denmark4 sites, 4 recruiting

  • Aalborg University Hospital ( Site 1302)

    Aalborg, North Denmark, 9000

    Study Coordinator, +4597662238

    Recruiting

  • University College Hospital, Department of Haematology ( Site 1303)

    Aarhus, Central Jutland, 8200

    Study Coordinator, +45 78455848

    Recruiting

  • Regionshospitalet Gødstrup ( Site 1301)

    Herning, Central Jutland, 7400

    Study Coordinator, +45 78430000

    Recruiting

  • Odense Universitetshospital ( Site 1304)

    Odense, Region Syddanmark, 5000

    Study Coordinator, +45 6541 1152

    Recruiting

Other trials in Denmark

Greece4 sites, 4 recruiting

  • University General Hospital of Alexandroupoli ( Site 1601)

    Alexandroupoli, Evros, 681 00

    Study Coordinator, 0030 2551353739

    Recruiting

  • Evangelismos General Hospital of Athens ( Site 1602)

    Athens, Attica, 106 76

    Study Coordinator, 0030 2132041721

    Recruiting

  • General Hospital of Athens "Laiko"-Hematology Department ( Site 1603)

    Athens, Attica, 115 26

    Study Coordinator, 0030 2136060981

    Recruiting

  • Attikon University General Hospital of Athens ( Site 1604)

    Athens, Attica, 124 62

    Study Coordinator, 0030 2105832318

    Recruiting

Other trials in Greece

Israel4 sites, 4 recruiting

  • Carmel Hospital ( Site 1903)

    Haifa, 3436212

    Study Coordinator, 04-8250844

    Recruiting

  • Hadassah Medical Center ( Site 1901)

    Jerusalem, 9112001

    Study Coordinator, 97226778180

    Recruiting

  • Sourasky Medical Center ( Site 1904)

    Tel Aviv, 6423906

    Study Coordinator, 9723-6973782

    Recruiting

  • Poria Medical Center ( Site 1902)

    Tiberias, 15208

    Study Coordinator, 972-4-662759

    Recruiting

Other trials in Israel

Romania4 sites, 3 recruiting

  • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 2402)

    Brasov, 500052

    Study Coordinator, +40268 960

    Recruiting

  • Spitalul Clinic Colțea ( Site 2401)

    Bucharest, Bucharest, 030171

    Completed

  • Institutul Oncologic Cluj ( Site 2404)

    Cluj-Napoca, Cluj, 4003437

    Study Coordinator, +40264598362

    Recruiting

  • Spital Judetean Sibiu ( Site 2405)

    Sibiu, 557260

    Study Coordinator, +40269215050

    Recruiting

Other trials in Romania

South Africa4 sites, 4 recruiting

  • Haemalife ( Site 2501)

    Cape Town, Western Cape, 7580

    Study Coordinator, +27 21 900 6277

    Recruiting

  • Groote Schuur Hospital ( Site 2504)

    Cape Town, Western Cape, 7925

    Study Coordinator, +27214043077

    Recruiting

  • LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2506)

    Pretoria, Gauteng, 0181

    Study Coordinator, +27 (0)12 346 6701

    Recruiting

  • Netcare Pretoria East Hospital ( Site 2502)

    Pretoria, Gauteng, 0181

    Study Coordinator, +27129932555

    Recruiting

Other trials in South Africa

Switzerland4 sites, 4 recruiting

  • Kantonspital Baden ( Site 2703)

    Baden, Canton of Aargau, 5404

    Study Coordinator, 0041564862111

    Recruiting

  • Ospedale Regionale Bellinzona e Valli ( Site 2701)

    Bellinzona, Canton Ticino, 6501

    Study Coordinator, +41 91 811 89 31

    Recruiting

  • Ospedale Italiano Lugano (OIL) ( Site 2705)

    Lugano, Canton Ticino, 6900

    Study Coordinator, 0041918118612

    Recruiting

  • Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 2702)

    Sankt Gallen, Canton of St. Gallen, 9000

    Study Coordinator, 41714941111

    Recruiting

Other trials in Switzerland

Guatemala3 sites, 3 recruiting

  • MEDI-K ( Site 0701)

    Guatemala City, 01009

    Study Coordinator, +50222912323

    Recruiting

  • CELAN,S.A ( Site 0702)

    Guatemala City, 01010

    Study Coordinator, +502 55275016

    Recruiting

  • Cen Integral Onco Gastro y Hemato Onco Guatemala S.A. ( Site 0703)

    Guatemala City, 01010

    Study Coordinator, +502 30147611

    Recruiting

Other trials in Guatemala

Netherlands3 sites, 3 recruiting

  • Meander Medisch Centrum ( Site 2101)

    Amersfoort, Utrecht, 3813 TZ

    Study Coordinator, +31(0)338502129

    Recruiting

  • Albert Schweitzer Ziekenhuis ( Site 2103)

    Dordrecht, South Holland, 3318 AT

    Study Coordinator, +31(0)786523013

    Recruiting

  • Leids Universitair Medisch Centrum ( Site 2106)

    Leiden, South Holland, 2333 ZA

    Study Coordinator, 0031715262261

    Recruiting

Other trials in Netherlands

Portugal3 sites, 3 recruiting

  • Unidade Local de Saude de Braga - Hospital de Braga ( Site 2306)

    Braga, 4710-243

    Study Coordinator, +351253 027 249

    Recruiting

  • Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2308)

    Lisbon, 1649-035

    Study Coordinator, +351 217 805 000

    Recruiting

  • Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2302)

    Porto, 4200-072

    Study Coordinator, +351 22 508 4000

    Recruiting

Other trials in Portugal

Thailand3 sites, 2 recruiting

  • Faculty of Medicine Siriraj Hospital ( Site 4001)

    Bangkoknoi, Bangkok, 10700

    Completed

  • Maharaj Nakorn Chiang Mai Hospital ( Site 4002)

    Muang, Chiang Mai, 50200

    Study Coordinator, +6653935488

    Recruiting

  • Chulalongkorn University ( Site 4003)

    Pathumwan, Bangkok, 10330

    Study Coordinator, +6622564000

    Recruiting

Other trials in Thailand

Belgium2 sites, 2 recruiting

  • AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 1102)

    Mechelen, Antwerpen, 2800

    Study Coordinator, +32(0)15/89.10.10

    Recruiting

  • ASBL CHU Helora - Hôpital de Mons - Site Kennedy ( Site 1103)

    Mons, Hainaut, 7000

    Study Coordinator, +3265413744

    Recruiting

Other trials in Belgium

Hong Kong2 sites, 2 recruiting

  • Princess Margaret Hospital ( Site 3202)

    Hong Kong

    Study Coordinator, 85229901111

    Recruiting

  • Queen Mary Hospital ( Site 3201)

    Hong Kong

    Study Coordinator, 85222553838

    Recruiting

Other trials in Hong Kong

Puerto Rico2 sites, 2 recruiting

  • Auxilio Mutuo Cancer Center ( Site 1001)

    San Juan, 00918

    Study Coordinator, 787 758 2000

    Recruiting

  • BRCR Global Puerto Rico - Caribbean Cancer Care ( Site 1003)

    Yauco, 00698

    Study Coordinator, 1 561 437 6038

    Recruiting

Other trials in Puerto Rico

Singapore2 sites, 2 recruiting

  • National University Hospital ( Site 3702)

    Singapore, Central Singapore, 119074

    Study Coordinator, 6569082222

    Recruiting

  • National Cancer Centre Singapore ( Site 3701)

    Singapore, Central Singapore, 168583

    Study Coordinator, 6564368000

    Recruiting

Other trials in Singapore

About this study

Official title: A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Being tested
Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar
Keywords
Lymphoma, Large B-Cell, Diffuse
Medical subject headings
Lymphoma, Large B-Cell, Diffuse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Zilovertamab vedotinBiological

    Also called MK-2140, VLS-101

    IV infusion

  • RituximabBiological

    Also called RITUXAN®

    IV infusion

  • CyclophosphamideDrug

    Also called CYTOXAN®, NEOSAR®

    IV infusion

  • DoxorubicinDrug

    Also called ADRIAMYCIN®

    IV infusion

  • Rituximab BiosimilarBiological

    Also called TRUXIMA®, RUXIENCE®, RIABNI®

    IV infusion

  • PrednisoneDrug

    Per Approved Product Label

  • PrednisoloneDrug

    Oral administration

  • VincristineDrug

    IV infusion

  • Rescue medicationDrug

    Participants receive rescue medication per approved product label. The rescue medication is granulocyte colony-stimulating factor (G-CSF).

  • MethylprednisoloneDrug

    Per Approved Product Label

Study groups in NCT06717347
Study groupRoleWhat they receive
Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP)ExperimentalParticipants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus they may receive 2 additional cycles of rituximab or biosimilar as determined by the investigator. Participants also receive 100 mg prednisone, prednisolone, or methylprednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).
Receives: Biological: Zilovertamab vedotin; Biological: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Biological: Rituximab Biosimilar; Drug: Prednisone; Drug: Prednisolone; Drug: Rescue medication; Drug: Methylprednisolone
Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP)Active comparatorParticipants receive 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar, 1.4 mg/m^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus they may receive 2 additional cycles of rituximab or biosimilar as determined by the investigator. Participants also receive 100 mg prednisone, prednisolone, or methylprednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).
Receives: Biological: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Biological: Rituximab Biosimilar; Drug: Prednisone; Drug: Prednisolone; Drug: Vincristine; Drug: Methylprednisolone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free survival (PFS)

    PFS is defined as the time from randomization to the first documented disease progression per Lugano response criteria by blinded independent central review (BICR) or death due to any cause, whichever occurs first.

    Measured: Up to ~ 50 months

Secondary outcomes (10)

  1. Complete Response at End of Treatment (CR at EOT)

    CR at EOT is defined as a CR per Lugano response criteria as assessed by BICR at end of treatment. Participants with missing data or who discontinue treatment or study prior to reaching EOT will be considered non-responders and included in the total number of participants.

    Measured: Up to ~ 32 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Measured: Up to ~ 74 months

  3. Event-free Survival (EFS)

    EFS is defined as the time from randomization to the first documented disease progression per Lugano response criteria by BICR, death due to any cause, initiation of a new anticancer therapy or a positive biopsy for residual disease, whichever occurs first.

    Measured: Up to ~ 74 months

  4. Duration of Complete Response (DurCR)

    For participants who demonstrate CR at EOT per Lugano response criteria by BICR, duration of complete response is defined as the time from the first documented evidence of CR at or before EOT until disease progression or death due to any cause, whichever occurs first.

    Measured: Up to ~ 74 months

  5. Number of Participants Who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.

    Measured: Up to ~ 9 months

  6. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

    Measured: Up to ~ 6 months

  7. Change From Baseline in Health-Related Quality Of Life (HRQoL) on Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Trial Outcome Index (TOI) Score

    The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life.

    Measured: Baseline and Week 25

  8. Change From Baseline in HRQoL on FACT-Lym Total Score

    The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life.

    Measured: Baseline and Week 25

  9. Change From Baseline in HRQoL on FACT-Lym Physical Wellbeing (PWB) Score

    The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life.

    Measured: Baseline and Week 25

  10. Change From Baseline in HRQoL on Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Neurotoxicity Subscale Score

    The FACT GOG-NTX provides a targeted assessment of symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity. It is an 11-item questionnaire designed to measure the neurotoxicity subscale. The scoring of FACT GOG-NTX is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. To produce a Neurotoxicity Subscale score (range 0-44), multiply the sum of the item scores by the number of items in the subscale, then divide by the number of items answered.

    Measured: Baseline and Week 25

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Dec 2024
  2. Study start27 Jan 2025
  3. Primary completion2 Jul 2029 (estimated)
  4. Study completion29 Mar 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,046 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06717347
Sponsor's protocol ID
2140-010
Other IDs
MK-2140-010, 2024-515566-13-00, U1111-1309-3971, jRCT2061240099
Status last verified
Oct 2026
First submitted
2 Dec 2024
Last updated
21 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Zilovertamab vedotin, Rituximab and Cyclophosphamide in people with Diffuse Large B-Cell Lymphoma, run by Merck Sharp & Dohme LLC at 285 sites in 35 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 285 sites in United States, China, Japan, France, Spain and 30 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Toll Free Number (1-888-577-8839, Trialsites@msd.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free survival (PFS) (time frame: Up to ~ 50 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06717347.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in